RELATED: Exact Sciences, Mayo Clinic launch 150,000-strong Cologuard study Earlier this month, Exact Sciences announced it would expand its diagnostics franchise into hereditary cancer screening, with the $190 million acquisition of PreventionGenetics. That company offers more than 5,000 DNA tests including germline and whole exome sequencing panels to help identify people who may carry an inherited risk for cancer or other diseases. At the time, Exact Sciences also said it signed a licensing deal with OncXerna Therapeutics to gain access to its tumor microenvironment panel and add it to its GEM ExTra tumor sequencing test. OncXerna's Xerna test aims to identify patients most likely to respond to certain immunotherapies, and Exact Sciences also said it plans to develop the test into a future companion diagnostic.